Intra-Cellular Therapies v. Dr. Reddy’s: CAPLYTA Lumateperone Patent Consolidation
Intra-Cellular Therapies filed suit against Dr. Reddy’s Laboratories in November 2024 over three patents protecting CAPLYTA (lumateperone) capsules — a branded antipsychotic. The case was consolidated within 70 days into a broader multi-defendant ANDA litigation already underway in the New Jersey District Court, joining actions against six other generic challengers.
Multi-front ANDA battle over CAPLYTA lumateperone funnels into single NJ action
On November 1, 2024, Intra-Cellular Therapies, Inc. (ITCI) filed Civil Action No. 3:24-cv-10236 in the District of New Jersey against Dr. Reddy’s Laboratories, Ltd., asserting infringement of three patents — US12128043B2, US12122792B2, and US12090155B2 — each covering formulations or methods related to lumateperone, the active ingredient in CAPLYTA capsules (10.5 mg, 21 mg, and 42 mg). CAPLYTA is an FDA-approved atypical antipsychotic indicated for schizophrenia and bipolar depression, making its patent estate commercially significant.
The case closed on January 10, 2025 — just 70 days after filing — not through a merits ruling but via judicial consolidation into lead action 3:24-cv-04264. That lead case, originally filed in March 2024 against Aurobindo, had already absorbed parallel ANDA actions against Alkem, Hetero, MSN, Sandoz, and Zydus. A second wave of related cases filed in August 2024 was similarly consolidated, making this November filing the latest entrant into what is now a unified, multi-defendant proceeding.
The rapid consolidation reflects standard case management practice in complex ANDA litigation where multiple generic filers challenge the same branded drug. The public record of this specific docket does not disclose whether Dr. Reddy’s ANDA was filed independently or jointly with other defendants. All substantive patent validity, claim scope, and infringement questions — including those relevant to the three asserted patents — will now be adjudicated within the consolidated proceeding, the outcome of which remains pending.
Filing to Case Consolidated in 70 days
Resolved via consolidation in 70 days — well below the median ANDA trial timeline of 2–3 years
Case consolidated: what the transfer into lead action means for both parties
Consolidation under Rule 42: one proceeding, many defendants
Federal Rule of Civil Procedure 42(a) permits courts to consolidate cases sharing common questions of law or fact. Here, the New Jersey District Court folded this action into lead case 3:24-cv-04264 because all defendants are challenging the same CAPLYTA patent estate through ANDA filings. Consolidation does not resolve the merits — it streamlines discovery, claim construction, and trial logistics across all generic challengers simultaneously.
Procedural — no merits rulingITCI gains efficiency but faces a multi-front validity challenge
Consolidation means ITCI must defend the same three lumateperone patents against seven or more generic challengers in a single coordinated action. While this avoids duplicative proceedings, it concentrates risk: a single adverse claim construction or invalidity finding would apply across all defendants. ITCI’s ability to maintain exclusivity for CAPLYTA depends entirely on the outcome of the consolidated proceeding.
High-stakes consolidated defenseDr. Reddy’s joins a unified challenge pool with shared discovery
As a consolidated defendant, Dr. Reddy’s benefits from shared invalidity arguments, joint claim construction briefing, and distributed litigation costs across co-defendants. However, it also cedes some individual strategic control. If the consolidated defendants collectively succeed in invalidating or designing around ITCI’s patents, Dr. Reddy’s ANDA could advance to FDA approval and generic market entry — a commercially significant outcome given CAPLYTA’s market position.
Shared risk, shared upsideCAPLYTA exclusivity window now turns on a single consolidated outcome
Lumateperone generated substantial revenue for ITCI, and the consolidated litigation now serves as the single gating event for generic entry across all seven challengers. The three asserted patents — with application numbers suggesting relatively recent filings — could extend exclusivity well beyond any initial exclusivity period. Pharmaceutical IP teams monitoring ANDA pipelines in the CNS antipsychotic space should track the consolidated docket at 3:24-cv-04264 as the definitive proceeding.
CNS antipsychotic generic entry riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intra-cellular Therapies, Inc. | Company | Biopharmaceutical company — holder of US12128043B2, US12122792B2, and US12090155B2 (CAPLYTA/lumateperone)Search in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Dr. Reddy’s Laboratories, Ltd. — global generic pharmaceutical manufacturer and ANDA filerSearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order confirms that this action raises common questions of law and fact with the lead proceeding — specifically, the validity and infringement of ITCI’s lumateperone patents under the Hatch-Waxman framework. No merits determination has been made in this docket. All substantive rulings, including claim construction, infringement analysis, and invalidity defenses, will issue from the consolidated lead action 3:24-cv-04264. Practitioners should monitor that docket for scheduling orders, Markman hearings, and any summary judgment proceedings.
US12128043B2, US12122792B2 & US12090155B2 — Lumateperone (CAPLYTA) formulation patents
The three asserted patents — US12128043B2, US12122792B2, and US12090155B2 — protect formulations and related aspects of lumateperone, an atypical antipsychotic marketed by ITCI as CAPLYTA. The patents correspond to application numbers US18/602981, US18/240951, and US18/494754, respectively, suggesting filings within the last several years, which is consistent with a strategy to extend protection on an established commercial product. Lumateperone acts on dopamine, serotonin, and glutamate receptors and is approved for schizophrenia and bipolar depression.
From a competitive standpoint, a three-patent assertion covering overlapping aspects of the same drug product is designed to create redundancy in exclusivity. Even if one patent is invalidated or designed around, the remaining two continue to block generic entry. For generic pharmaceutical companies, this multi-layered estate makes ANDA prosecution and litigation strategy significantly more complex. IP teams tracking CNS drug patent estates should examine the claim scope of each patent independently, as validity and enforceability arguments may differ substantially across the three.
Should you run an FTO against US12128043B2, US12122792B2, and US12090155B2?
Any company developing, manufacturing, or distributing a lumateperone-containing drug product — including ANDA filers, 505(b)(2) applicants, or international generic manufacturers — should conduct a freedom-to-operate analysis against all three asserted patents. The consolidated litigation confirms that ITCI is actively enforcing this estate against at least seven generic challengers. The claims of each patent should be assessed independently for scope and validity risk.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim landscape across US12128043B2, US12122792B2, and US12090155B2, identify prior art relevant to invalidity arguments, and surface related Orange Book-listed patents in the lumateperone estate. R&D and regulatory teams can use Eureka to model design-around options and benchmark the claim scope against issued formulation patents in the broader CNS antipsychotic segment.
Run a freedom-to-operate analysis on US12128043B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent litigation over CNS antipsychotic formulations in New Jersey
Explore comparable Hatch-Waxman infringement actions in the New Jersey District Court involving CNS and antipsychotic drug patent estates with multi-defendant consolidation.
What this case signals for the CNS pharmaceutical ANDA IP landscape
ITCI’s coordinated multi-defendant filing strategy reflects a deliberate approach to defending CAPLYTA’s patent estate against a wave of generic challengers.
Staggered ANDA filings prompt staggered suits — then consolidation
ITCI filed multiple waves of litigation in March, August, and November 2024, consistent with generic challengers filing ANDAs on a rolling basis. Brand holders should anticipate consolidation and structure early filings to establish favorable lead-case positioning, including judge assignment and claim construction schedule.
Three patents on one product signals layered exclusivity strategy
Asserting US12128043B2, US12122792B2, and US12090155B2 together — all covering lumateperone formulations — suggests ITCI is pursuing a patent thicket approach. Competitors and generic filers should conduct granular claim differentiation analysis across all three patents before designing any work-around strategy.
Intra-cellular v Dr. — key questions answered
ITCI filed patent infringement claims against Dr. Reddy’s in November 2024 over three CAPLYTA (lumateperone) patents. The case was closed after 70 days via consolidation into lead action 3:24-cv-04264, which encompasses parallel ANDA litigation against multiple generic challengers. No merits ruling was issued in this specific docket.
ITCI asserted US12128043B2 (application US18/602981), US12122792B2 (application US18/240951), and US12090155B2 (application US18/494754). All three patents cover formulations or related aspects of lumateperone, the active ingredient in CAPLYTA capsules approved for schizophrenia and bipolar depression.
Consolidation under Rule 42(a) means the New Jersey District Court merged this action with lead case 3:24-cv-04264 because all defendants challenge the same CAPLYTA patent estate. Substantive issues — including claim construction, validity, and infringement — will be resolved in the consolidated proceeding. The consolidation is procedural and does not constitute a merits ruling.
The consolidated proceeding includes Aurobindo, Alkem, Hetero, MSN, Sandoz, and Zydus as co-defendants alongside Dr. Reddy’s Laboratories. ITCI filed actions against these defendants in waves between March and November 2024, with all cases subsequently consolidated into lead docket 3:24-cv-04264 in the District of New Jersey.
CAPLYTA (lumateperone) is a commercially significant CNS antipsychotic generating substantial revenue for ITCI. The three asserted patents represent a layered exclusivity strategy. Successful enforcement would delay generic entry across all seven ANDA challengers. Failure to sustain any or all three patents could open the market to generic competition simultaneously from multiple filers.
PatSnap Eureka searches patents and litigation data to answer instantly.